C. Moore

发表

Poor record linkage sensitivity biased outcomes in a linked cohort analysis.

M. Law, J. Amin, Cecilia L. Moore, 2016, Journal of clinical epidemiology.

ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing

J. Seeley, C. Giaquinto, O. Kobusingye, 2021, BMC Infectious Diseases.

Metabolic Profiles of Individuals Switched to Second-Line Antiretroviral Therapy after Failing Standard First-Line Therapy for Treatment of HIV-1 Infection in a Randomized, Controlled Trial

D. Cooper, S. Kerr, S. Emery, 2017, Antiviral therapy.

Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy

D. Cooper, P. Phanuphak, S. Emery, 2013, AIDS.

Bone Mineral Density Over 96 Weeks in Adults Failing First-Line Therapy Randomized to Raltegravir/Lopinavir/Ritonavir Compared With Standard Second-Line Therapy

D. Cooper, P. Phanuphak, S. Emery, 2014, Journal of acquired immune deficiency syndromes.

Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial

Ian R. White, R. Turner, H. Mujuru, 2022, BMC Medical Research Methodology.

Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy

B. Gazzard, D. Cooper, J. Amin, 2018, AIDS.

A New Method for Assessing How Sensitivity and Specificity of Linkage Studies Affects Estimation

M. Law, J. Amin, Cecilia L. Moore, 2014, PloS one.

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

Ana C. Matos, C. Königs, C. Giaquinto, 2022, The lancet. HIV.

Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels

V. Natarajan, D. Cooper, A. Kelleher, 2015, AIDS.

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

Ana C. Matos, C. Königs, J. Seeley, 2022, The lancet. HIV.

Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.

K. Ruxrungtham, D. Cooper, H. Teppler, 2015, The lancet. HIV.

Hospitalization for Anxiety and Mood Disorders in HIV-Infected and -Uninfected Gay and Bisexual Men

M. Law, J. Amin, K. Petoumenos, 2016, Journal of acquired immune deficiency syndromes.

Hospitalisation rates and associated factors in community‐based cohorts of HIV‐infected and ‐uninfected gay and bisexual men

J. Amin, K. Petoumenos, M. Law, 2016, HIV medicine.

Patterns of Drug Use and Drug-related Hospital Admissions in HIV-Positive and -Negative Gay and Bisexual Men

M. Law, J. Amin, K. Petoumenos, 2016, AIDS and Behavior.

Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial

C. Giaquinto, H. Mujuru, D. Gibb, 2020, The lancet. HIV.

Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

C. Giaquinto, H. Mujuru, D. Gibb, 2022, The lancet. HIV.

Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferio

D. Cooper, H. Teppler, S. Kerr, 2013, The Lancet.

Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study.

D. Cooper, H. Teppler, S. Emery, 2016, AIDS research and human retroviruses.

Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions.

A. Crook, S. McCormack, Felipe García, 2019, The lancet. HIV.

The evaluation of immune-based approaches to achieve an antiretroviral therapy (ART)-free remission of HIV infection requires demonstration of efficacy through ART interruption placebo-controlled trials

A. Crook, S. McCormack, Felipe García, 2019 .

HIV Lipodystrophy in Participants Randomised to Lopinavir/Ritonavir (LPV/r) +2–3 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) or LPV/r + Raltegravir as Second-Line Antiretroviral Therapy

D. Cooper, P. Phanuphak, S. Emery, 2013, PloS one.

Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection

D. Cooper, H. Teppler, S. Kerr, 2015, PloS one.

Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy

D. Cooper, P. Phanuphak, S. Emery, 2017, The lancet. HIV.

Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial

C. Giaquinto, N. Klein, T. Bunupuradah, 2018, PloS one.